Helicobacter pylori neutrophil-activating protein (HP-NAP) is a virulence factor that activates phagocytic NADPH-oxidase. The effect of HP-NAP on the production of tissue factor (TF), plasminogen activator inhibitor-2 (PAI-2), and urokinase-type plasminogen activator (u-PA) by human blood mononuclear cells (MNC) was evaluated by using functional and immunological assays and mRNA analysis. HP-NAP induced time-and dose-dependent increases in TF and PAI-2, with a maximal effect at 300 nmol/L (115-fold increase in antigens). No changes in u-PA were observed. When whole bacteria were used, an H. pylori mutant lacking HP-NAP was significantly less active than the wild-type strain. MNC from a patient with chronic granulomatous disease behaved as do normal cells, which indicates that HP-NAP effects can occur independently of NADPH-oxidase. HP-NAP, by inducing the coordinate expression of cell procoagulant and antifibrinolytic activities, might favor fibrin deposition and contribute to the inflammatory reaction of gastric mucosa elicited by H. pylori.
for the production of interleukin (IL)-8 [11] [12] [13] [14] and cyclooxigenase-2 synthase, a phenomenon that is believed to favor neoplastic progression [15] . Other virulence factors are encoded outside the pathogenicity island. Among them, vacuolating cytotoxin A and H. pylori neutrophil-activating protein (HP-NAP) are linked to pathogenicity and are candidates for a recombinant anti-H. pylori vaccine [16] .
HP-NAP is a dodecameric protein consisting of 17,000-Da monomers with a central cavity where iron can be accumulated [17, 18] . This bacterial cytosolic protein, encoded by the napA gene, is released in the medium, most likely after cell lysis, and binds to the bacterial surface, where it can act as an adhesin, mediating binding to mucin [19] or to PMNG sphingomyelin [20] . HP-NAP also shows intrinsic proinflammatory activities, is chemotactic for PMNG and monocytes, and induces, in both, surface expression of b 2 -integrins, which are necessary for endothelial transmigration [21] . Moreover, it triggers the production of reactive oxygen intermediates through the activation of NADPH-oxidase [17, 21] . On the basis of this evidence, it has been postulated that HP-NAP contributes significantly to the exacerbation of tissue inflammatory reactions and, therefore, to the tissue damage that accompanies chronic H. pylori infection [21] . The possibility that H. pylori surface proteins promote inflammation also is suggested by their triggering of IL-1 and tumor necrosis factor-a production by mononuclear cells (MNC) [22] .
On activation, monocytes express on their surface the 47,000-Da transmembrane protein tissue factor (TF) that is a potent trigger of the protease cascade that leads to fibrin deposition [23] [24] [25] [26] . Various agents induce TF expression through a protein tyrosine kinase (PTK)-and protein kinase C (PKC)-dependent pathway that eventually leads to activation of NF-kB [24] [25] [26] . In addition, monocytes also can regulate fibrinolysis by secreting the urokinase-type plasminogen activator (u-PA) and by expressing specific receptors for u-PA and plasminogen, thus leading to efficient plasmin generation on the cell surface [27] . Plasmin is a serine protease of broad specificity, capable of degrading fibrin and other protein components of the extracellular matrix and basement membrane and of activating the complement cascade [27] . Monocytes also produce plasminogen activator inhibitors (PAIs), PAI-2 in particular, a serpin that regulates u-PA activity [28] . These various biological functions allow monocytes to modulate fibrin formation and deposition at tissue level. Available evidence indicates that monocyte-regulated fibrin turnover plays a major role in different pathological conditions, including infections, malignancy, and atherothrombotic disease [29] [30] [31] . It has been shown elsewhere that H. pylori lipopolysaccharide (LPS) induces TF and PAI-2 production in human MNC [32] ; however, as demonstrated in other biologic systems, too [33] , the potency of H. pylori LPS was much lower than that of LPSs from other intestinal gram-negative bacteria. The latter finding underscores the possibility that virulence factors of H. pylori other than LPS might be involved in monocyte-mediated fibrin turnover during H. pylori infection. The aim of the present study was to investigate the effect of HP-NAP on the production of TF and fibrinolytic components by human blood MNC.
Materials and Methods
Incubation of isolated MNC with HP-NAP. MNC were obtained from citrated blood drawn from healthy donors and from a patient with X-linked chronic granulomatous disease (CGD). All subjects had abstained from all medications for у1 week before blood collection. Cells were isolated by centrifugation on a Ficoll-Hypaque (Nycomed Pharma) cushion [34] and were suspended in LPS-free RPMI-1640 (Bio Whittaker) at a concentration of /mL, unless 6 3 ϫ 10 otherwise specified. Final cell preparations contained 197% MNC and !1 platelet per nucleated cell. Monocytes, identified by nonspecific esterase staining, were 18%-30% (mean, 24%) of the MNC. In some experiments, MNC were further enriched in monocytes by adherence [35] . Cell viability, assessed by the trypan blue test, always exceeded 96%. All reagents were free of endotoxin, as assessed by the lymulus amebocyte lysate assay (Sigma).
HP-NAP was produced in recombinant form from Bacillus subtilis [18] . To evaluate its effect on the cell procoagulant and fibrinolytic properties, aliquots of cell preparations in serum-free RPMI medium were incubated at 37ЊC with varying doses of HP-NAP. Controls were done by incubating cells with equivalent aliquots of PBS (pH 7.4) used to dissolve HP-NAP. For comparison, cells also were treated with 1 mg/mL LPS from Salmonella typhimurium (Sigma), a concentration that has been shown to induce maximal TF and PAI-2 production in MNC [32] . At the indicated times, samples were collected and were processed, as described below, before assay. In some experiments, MNC were stimulated in the presence of 10% (v/v) fetal calf serum or of serum plus 5 mg/mL of an anti-CD14 monoclonal antibody (MY4; Coulter Immunology). In the latter experiments, the cells were washed and were suspended in serum-free RPMI medium before assay.
Quantification of TF activity and antigen in MNC. Unless otherwise stated, all assays for TF activity were done with lysed MNC (obtained by triple freezing and thawing). TF activity was measured by a 1-stage clotting assay, as described elsewhere [36] . Clotting times were converted to TF arbitrary units by comparison with a standard curve constructed with commercial human thromboplastin (Thromborel; Dade-Behring). Because the monocyte is the only cell type among the MNC that can express procoagulant properties [26, 36] 3 ϫ 10 100 mmol/L NaCl, pH 7.5) containing 1% (v/v) Triton X-100 for 4 h at 4ЊC. Results were expressed as pg/10 5 monocytes, calculated from a calibration curve obtained with the standard TF provided.
Quantification of PAI-2 and u-PA in MNC. The amount of PAI-2 and u-PA antigens was determined in extracellular media and in cell lysates by commercially available ELISAs, following the manufacturer's instructions (Biopool).
Fibrin autography. For zymography, extracellular media were collected after 20 h of incubation with agonists and were run in nonreducing 10% SDS-PAGE. To visualize PAIs, media were preincubated with exogenous u-PA (2.5 U/mL) for 30 min at room temperature (RT) before electrophoresis. Gels then were soaked at RT for 60 min in Triton X-100 (2.5% v/v in H 2 O), were washed for 45 min in H 2 O, and were placed on 1% (w/v) agarose films containing plasminogen and fibrin, as described elsewhere [37] . After overnight incubation at RT, bands corresponding to free and bound plasminogen activators were visualized by the appearance of lysis areas in the fibrin gel.
In vitro clot lysis. The effect of MNC on u-PA-induced clot lysis was studied, using a microplate turbidimetric assay, as described elsewhere [38] . In brief, cells were stimulated overnight with 300 nmol/L HP-NAP or with buffer alone. Aliquots (100 mL) of cell suspensions were added to 95 mL of human fibrinogen (6 mg/ mL), 5 mL of citrated human plasma, 10 mL of a mixture of phospholipids (Thrombofax; Instrumentation Laboratory), 10 mL of u-PA (final concentration, 12.5 U/mL), or tissue-type plasminogen activator (t-PA; final concentration, 50 ng/mL, corresponding to ∼5 U/mL of u-PA [39] ), and 10 mL of 0.5 mol/L CaCl 2 in a 96-well microplate tray and were incubated at 37ЊC. The decrease in optical density at 405 nm, after the initial increase due to clot formation, was measured every 15 min, and the time necessary to reach a 50% decrease, corresponding to 50% fibrinolysis, was determined. Where indicated, neutralizing rabbit anti-PAI-2 IgG (provided by N. Booth, Dept. of Molecular and Cell Biology, University of Aberdeen, Aberdeen, United Kingdom) or control rabbit IgG was added to the sample before the clot lysis assay, at a final concentration of 20 mg/mL.
Northern blotting. RNA was extracted from MNC ( 6 10 ϫ 10 cells) incubated for 4 h with HP-NAP or solvent, as described elsewhere [40] . Fifteen micrograms of each RNA sample was used for analysis. Detection of TF and PAI-2 mRNA was done by using a 790-bp Xba1-EcoR1 fragment from pSP64 (PAI-2; provided by S. Moll and D. Belin, Laboratory of Nephrology, Genève, France, courtesy of L. Gesualdo, Dept. Dell'Emergenza e dei Trapianti di Organi, University of Bari, Bari, Italy) and a 1200-bp Sal1 fragment from pUC18 (TF; provided by R. Lorenzet, Mario Negri Institute, Santa Maria Imbaro, Italy) as probes. Relative RNA loading was determined by examination of ethidium bromidestained gels.
Inhibitors. MNC were preincubated at 37ЊC with 1-(5 isoquinolinesulfonyl)-2-methyl-piperazine (H7; 180 mmol/L) for 15 min, with genistein (100 mmol/L) for 15 min, with caffeic acid phenethyl ester (CAPE; 90 mmol/L) for 120 min, or with 4-hydroxynonenal (HNE; 25 mmol/L) for 60 min, and then were exposed to HP-NAP for 4 or 20 h. None of the inhibitors influenced TF and PAI-2 production in the absence of HP-NAP.
Bacterial strains and culture conditions. H. pylori DnapA isogenic mutant of H. pylori strain 342 was obtained by allelic exchange with a pJMR1 vector carrying a kanamycin resistance cassette inserted into the napA gene (authors' unpublished data). Wild-type (wt) and mutant bacteria were grown on Columbia agar plates supplemented with antibiotics [41] and were incubated at 37ЊC under moist microerophilic atmosphere in an oxoid anerobic jar containing a gas-generating kit (Unipath Limited). After 2-3 days, bacteria were collected in LPS-free RPMI medium, were washed in the same medium, and were added to MNC. Bacterial colony-forming unit titer was determined by measuring the optical density at 600 nm and comparing its value to a standard curve, as described elsewhere [41] .
Statistical methods. Data are expressed as the . mean ‫ע‬ SE Difference between means was assessed by the paired Student's t test.
was considered to be statistically significant. P ! .05
Results

Effect of HP-NAP on TF expression by MNC.
Human MNC were treated with different concentrations of purified HP-NAP for 4 h and then were tested for TF activity. Figure 1A shows that HP-NAP increases the TF activity of MNC dose dependently, with a half-maximal effect at the concentration of 100 nmol/L (calculation based on the 17,000-Da monomer). The maximal effect was obtained at the concentration of 300 nmol/L and corresponded to ∼1300 TF units, a value comparable to that (∼1500 TF units) induced in the same conditions by the powerful TF inducer S. typhimurium LPS (1 mg/mL). When a clotting assay was done with intact HP-NAP-treated MNC, TF activity was 2-5-fold lower than that of corresponding lysed cells at all tested HP-NAP concentrations (data not shown). By using plasma samples deficient in single coagulation factors [36] , this activity was found to be totally dependent on factor VII and thus functionally identical to TF (data not shown). Similar results were obtained with monocyte-enriched preparations (85%-95%), which suggests that the effect of HP-NAP is not influenced by the presence of lymphocytes to a significant extent. Enhanced TF expression in HP-NAPstimulated MNC also was demonstrated by Northern blot analysis and ELISA ( figure 1A) . After 4 h of incubation with HP-NAP, TF mRNA exhibited a dose-dependent increase, whereas it was undetectable in control cells. Ethidium bromide staining of ribosomal RNA applied to each lane resulted in bands of similar intensity (data not shown), which confirms that equivalent amounts of cellular RNA had been loaded onto each lane. TF antigen increased after stimulation with HP-NAP for 4 h, reaching a maximal value at 300 nmol/L. Time-course experiments with HP-NAP (50 nmol/L) showed a detectable increase in TF activity only after a 1.5-h stimulation (figure 1B), a lag time compatible with activation of gene transcription and pro- tein synthesis. TF activity augmented rapidly thereafter, reaching a plateau 20 h after the addition of HP-NAP. Figure 2 shows that the induction of MNC TF activity was totally abolished by heat denaturation of HP-NAP (100ЊC for 10 min). Moreover, the HP-NAP effect was not influenced by the presence of serum in the culture medium or the inclusion of a blocking anti-CD14 antibody in serum-containing medium, thus ruling out a possible role of contaminating LPS in the HP-NAP action. Indeed, the stimulating activity of S. typhimurium LPS was unaffected by heat-treatment (data not shown) and was potentiated by serum and inhibited by anti-CD14 antibodies [32] .
Effect of HP-NAP on PAI-2 and u-PA production by MNC. Incubation of MNC with HP-NAP for 20 h caused a dosedependent increase of PAI-2 antigen accumulation in the extracellular medium ( figure 3A) . Also, in this case, the effect of the highest doses of HP-NAP was comparable to that of S. typhimurium LPS (1 mg/mL). Intracellular PAI-2 was also increased by HP-NAP, mean levels in cell extracts being about twice as high as those of the extracellular inhibitor (data not shown). In contrast, extracellular ( figure 3A) , as well as cellassociated (data not shown), u-PA antigen was not affected by HP-NAP at any concentration. The dose-response curve of HP-NAP-induced increase of PAI-2 antigen and mRNA was very similar to that of TF ( figure 3A and figure 1A) , with a halfmaximal effect at 100 nmol/L.
Fibrin autography of the extracellular medium derived from control and HP-NAP-stimulated MNC showed no visible lysis bands (figure 3B). When extracellular medium was preincubated with purified u-PA before electrophoresis, however, the activator migrated exclusively as free enzyme in control samples but both as free molecule and as u-PA-inhibitor complex in HP-NAP-stimulated samples (figure 3B), which is compatible with the presence of PAI-2 antigen in the latter.
Effect of HP-NAP-treated MNC on plasma clot lysis. To assess whether the increased production of PAI-2 induced by HP-NAP had functional consequences on fibrinolysis, we evaluated the effect of MNC incubated for 20 h with HP-NAP (300 nmol/L) on the lysis of diluted plasma clots by exogenous u-PA. As shown in figure 4 , HP-NAP-treated cells markedly re- tarded u-PA-induced clot lysis, whereas control cells were almost ineffective. Moreover, HP-NAP-treated cells did not affect clot lysis induced by single-chain t-PA, an activator that is poorly inhibited by PAI-2 [42] . The addition of neutralizing anti-PAI-2 antibodies (20 mg/mL) to the clot lysis system almost completely abolished the inhibitory effect of HP-NAP-treated MNC, whereas normal rabbit IgG had no effect (data not shown). Neither control nor HP-NAP-treated MNC caused clot lysis in the absence of u-PA (data not shown).
Effect of HP-NAP-producing H. pylori strain and of its isogenic mutant on the production of TF and PAI-2 by MNC.
MNC were infected for 4 h with increasing doses of living bacteria and then were tested for their TF content. The HP-NAP-producing H. pylori strain 342 was significantly more active in stimulating the expression of both TF antigen ( figure  5A ) and activity (data not shown) than was its corresponding isogenic mutant with a disrupted napA gene. PAI-2 accumulation in the extracellular medium was clearly enhanced after infection for 20 h, with HP-NAP-producing bacteria only at concentrations of and cfu/mL. At these con- 5 5 1 ϫ 10 5 ϫ 10 centrations, the DnapA isogenic mutant induced significantly less PAI-2 release than did the wt strain ( figure 5B) .
Effect of inhibitors of signal transduction pathways on the HP-NAP-induced production of TF and PAI-2 by MNC.
The signal transduction pathways involved in the HP-NAP-stimulated increase of TF and PAI-2 expression was investigated pharmacologically. As shown in figure 6 , incubation of MNC with the PTK inhibitor genistein [25] or with the PKC inhibitor H7 [24] resulted in a strong inhibition of TF increase induced by HP-NAP. CAPE and HNE, which interfere with the activation of NF-kB [43, 44] , also completely blocked HP-NAP-induced TF. PAI-2 production, on HP-NAP incubation, was similarly inhibited by all of the above drugs, with the exception of genistein, which had a partial effect (50% inhibition).
Effect of HP-NAP on CGD MNC. The possibility that NADPH-oxidase activation mediates the induction of TF and PAI-2 expression, by increasing the levels of reactive oxygen intermediates within the cell, was investigated by evaluating the effect of HP-NAP on MNC from a patient with CGD. TF and PAI-2 antigen production in CGD cells incubated with HP-NAP (300 nmol/L) for 4 and 20 h amounted to 2450 pg/10 5 monocytes and 133 ng/10 5 monocytes, respectively. These values are comparable to those obtained with the same concentration of HP-NAP in normal cells ( figure 1 and figure 3) . Moreover, the effect of signal transduction inhibitors genistein, H7, CAPE, and HNE on HP-NAP-induced responses in CGD MNC was similar to that observed in normal cells (data not shown).
Discussion
In recent years, HP-NAP has emerged as an important virulence factor of H. pylori because of its ability to recruit both PMNG and MNC through its chemotactic activity and to stimulate these cells to produce NADPH-oxidase-dependent reactive oxygen intermediates [17, 21] . This study demonstrates that HP-NAP efficiently stimulates human blood MNC to synthesize TF and PAI-2 without altering u-PA production, as indicated by protein determination and mRNA analysis. Clotting assays established that HP-NAP-induced TF is functionally active, thus triggering blood clotting activation and promoting fibrin formation. That up-regulation of PAI-2 results in impaired proteolysis in the cell environment is indicated by the capacity of HP-NAP-treated MNC to inhibit u-PA-induced plasma clot lysis markedly. This effect indeed was due to cell-derived PAI-2, because no inhibition of clot lysis was observed when single-chain t-PA, which interacts poorly with PAI-2 [42] , was used instead of u-PA or when neutralizing anti-PAI-2 antibodies were added to the assay system. It should be stressed that, in our experiments, the maximal effect is observed with HP-NAP concentrations (300 nmol/L) that are ∼10-fold lower than those reported to exert chemotactic activity and to activate NADPH-oxidase [21] . Moreover, in view of the fact that the HP-NAP concentrations were calculated on the basis of the 17,000-Da monomer, the actual molar concentration of the dodecameric protein is 12-fold lower. This implies that a significant response of MNC can be elicited by concentrations of HP-NAP (dodecameric protein) as low as 5 nmol/L (i.e., by concentrations that might be reached in vivo).
The possibility that endotoxin contamination, although not detectable with the limulus assay, was responsible for or contributed to the observed HP-NAP-induced responses is ruled out by the following observations. First, heat treatment of HP-NAP resulted in a complete loss of its stimulating activity. Second, the procoagulant response of MNC to HP-NAP was not influenced by the presence of serum in the culture medium or by the addition of an anti-CD14 antibody in serum-containing medium. This is at variance with the procoagulant response of MNC to LPS, which is greatly potentiated by serum because of the binding of LPS to a serum factor termed LPS-binding protein (LBP) and because of the subsequent engagement of the membrane receptor CD14 by LPS-LBP complex [32, 45] . Cell wall LPS has been proposed as a potential pathogenic factor in H. pylori infection, and there is evidence that H. pylori LPS induces TF and PAI-2 production in MNC, although it is much less active than other enterobacterial LPSs [32] . To evaluate the relative contribution of HP-NAP in MNC stimulation, we compared the effect of a DnapA isogenic mutant of H. pylori with that of the corresponding wt bacteria. It is interesting that bacteria that lack HP-NAP were significantly less active than were wt bacteria in stimulating both TF and PAI-2 synthesis by MNC. Considering that whole bacteria may induce TF expression in MNC by complex mechanisms, including bacterial phagocytosis [46] , our observation strengthens the prominent role of HP-NAP as an inducer of TF and PAI-2 synthesis.
HP-NAP binds to an unidentified receptor, coupled to trimeric GTPases, and generates intracellular signals [21] . In this study, we show that the transduction pathway(s) triggered by HP-NAP eventually leads to TF and PAI-2 gene activation. In agreement with data previously obtained with other agonists [24, 25] , this gene activation requires PTK and PKC activation and NF-kB. In fact, TF expression induced by HP-NAP is fully prevented by genistein and H7, which inhibit PTK and PKC, respectively, as well as by CAPE and HNE, 2 agents that prevent NF-kB release and nuclear translocation [43, 44] . The observation that MNC from a patient with CGD, which lacked NADPH-oxidase, behave as normal cells when stimulated by HP-NAP indicates that activation of NADPH-oxidase, one of the best characterized actions of HP-NAP [21] , does not contribute to a significant extent to the induction of TF and PAI-2. Our data also show that the intracellular pathway triggered by HP-NAP that leads to PAI-2 synthesis is partially different from the pathway that triggers TF expression. In fact, PAI-2 induction, like TF induction, requires PKC but is much less sensitive to PTK activity.
Taken together, these results support the hypothesis that HP-NAP is a major virulence factor of H. pylori that is capable of increasing the procoagulant potential and of inhibiting the fibrinolytic capacity of MNC, thus tilting the cell coagulationfibrinolysis balance toward fibrin formation and persistence. This is achieved by the induction of parallel intracellular pathways that lead to activation of TF and PAI-2 gene transcription. Hence, in addition to the factors encoded within the pathogenicity island cag, HP-NAP must be included in the category of virulence determinants that alter the gene regulation of host cells, with the possible role of supporting H. pylori colonization. The action of HP-NAP described here is expected to favor chronic development of gastritis and tissue disruption by hampering tissue healing, which requires degradation and removal of fibrin and tissue debris. At the same time, fibrin deposition might hinder movement of phagocytes toward H. pylori cells and protect them from phagocytosis.
Expression of TF on mononuclear phagocytes also has an important role in the formation of atheromatous plaques, both at early stages, during monocyte-endothelium interaction and transmigration, and in their subsequent development [31, [47] [48] [49] . It can be speculated that, in patients infected with H. pylori, monocytes are stimulated by HP-NAP to express TF and PAI-2 either in the inflamed gastric microcirculation or in the interstitial space, whereupon they can return to the bloodstream via a TF-dependent reverse endothelial transmigration [48] . Such a pool of activated circulating monocytes, which are prone to trigger coagulation, would be expected to favor the growth of atheromatous plaques, as recently suggested by a study of patients with angina [50] , and might represent one of the factors responsible for the known increased risk of ischemic diseases associated with H. pylori infection [5, 6] .
